Search

Your search keyword '"Hsueh, Eddy C"' showing total 273 results
Start Over Author "Hsueh, Eddy C"
273 results on '"Hsueh, Eddy C"'

6. Integrating 31-Gene Expression Profiling With Clinicopathologic Features to Optimize Cutaneous Melanoma Sentinel Lymph Node Metastasis Prediction

Author

Whitman, Eric D., Koshenkov, Vadim P., Gastman, Brian R., Lewis, Deri, Hsueh, Eddy C., Pak, Ho, Trezona, Thomas P., Davidson, Robert S., McPhee, Michael, Guenther, J. Michael, Toomey, Paul, Smith, Franz O., Beitsch, Peter D., Lewis, James M., Ward, Andrew, Young, Shawn E., Shah, Parth K., Quick, Ann P., Martin, Brian J., Zolochevska, Olga, Covington, Kyle R., Monzon, Federico A., Goldberg, Matthew S., Cook, Robert W., Fleming, Martin D., Hyams, David M., and Vetto, John T.

Published
2021
Full Text
View/download PDF

8. Data from Oxidized Lipoproteins Promote Resistance to Cancer Immunotherapy Independent of Patient Obesity

Author

Khojandi, Niloufar, primary, Kuehm, Lindsey M., primary, Piening, Alexander, primary, Donlin, Maureen J., primary, Hsueh, Eddy C., primary, Schwartz, Theresa L., primary, Farrell, Kaitlin, primary, Richart, John M., primary, Geerling, Elizabeth, primary, Pinto, Amelia K., primary, George, Sarah L., primary, Albert, Carolyn J., primary, Ford, David A., primary, Chen, Xiufen, primary, Kline, Justin, primary, and Teague, Ryan M., primary

Published
2023
Full Text
View/download PDF

9. Supplemental Figures from Oxidized Lipoproteins Promote Resistance to Cancer Immunotherapy Independent of Patient Obesity

Author

Khojandi, Niloufar, primary, Kuehm, Lindsey M., primary, Piening, Alexander, primary, Donlin, Maureen J., primary, Hsueh, Eddy C., primary, Schwartz, Theresa L., primary, Farrell, Kaitlin, primary, Richart, John M., primary, Geerling, Elizabeth, primary, Pinto, Amelia K., primary, George, Sarah L., primary, Albert, Carolyn J., primary, Ford, David A., primary, Chen, Xiufen, primary, Kline, Justin, primary, and Teague, Ryan M., primary

Published
2023
Full Text
View/download PDF

18. Optimizing treatment approaches for patients with cutaneous melanoma by integrating clinical and pathologic features with the 31-gene expression profile test

Author

Jarell, Abel, primary, Gastman, Brian R., additional, Dillon, Larry D., additional, Hsueh, Eddy C., additional, Podlipnik, Sebastian, additional, Covington, Kyle R., additional, Cook, Robert W., additional, Bailey, Christine N., additional, Quick, Ann P., additional, Martin, Brian J., additional, Kurley, Sarah J., additional, Goldberg, Matthew S., additional, and Puig, Susana, additional

Published
2022
Full Text
View/download PDF

19. The Impact of Smoking on Sentinel Node Metastasis of Primary Cutaneous Melanoma

Author

Jones, Maris S., Jones, Peter C., Stern, Stacey L., Elashoff, David, Hoon, Dave S. B., Thompson, John, Mozzillo, Nicola, Nieweg, Omgo E., Noyes, Dirk, Hoekstra, Harald J., Zager, Jonathan S., Roses, Daniel F., Testori, Alessandro, Coventry, Brendon J., Smithers, Mark B., Andtbacka, Robert, Agnese, Doreen, Schultz, Erwin, Hsueh, Eddy C., Kelley, Mark, Schneebaum, Schlomo, Jacobs, Lisa, Bowles, Tawnya, Kashani-Sabet, Mohammed, Johnson, Douglas, and Faries, Mark B.

Published
2017
Full Text
View/download PDF

20. Additional file 1 of SALL1 functions as a tumor suppressor in breast cancer by regulating cancer cell senescence and metastasis through the NuRD complex

Author

Ma, Chunling, Wang, Fang, Han, Bing, Zhong, Xiaoli, Si, Fusheng, Ye, Jian, Hsueh, Eddy C., Robbins, Lynn, Kiefer, Susan M., Zhang, Yanping, Hunborg, Pamela, Varvares, Mark A., Rauchman, Michael, and Peng, Guangyong

Abstract

Figure S1. SALL1 and SALL4 expression levels in different types of human cancers. (A) SALL1 expression in tumor cells in breast cancer and melanoma tissues was determined using the immunohistochemical staining. Numbers of SALL1+ tumor cells in melanoma tissues were much higher than those in breast cancer tissues. Expression level of each dot shown in the right panel is the average numbers of SALL1+ cells per high field (400 x) in each tissue sample. The median number of SALL1+ cells in each group is shown as a horizontal line. Significance was determined by unpaired T test. (B) The COSMIC analysis shows the mutations and the promoter methylation status of SALL1 gene in breast cancer tissues. (C) SALL1 promoter genes are highly methylated in the primary breast cancer tissues comparison with solid normal tissues. The 2 specific molecular probes which span the proximal promoter region of SALL1 gene were selected based on the information in COSMIC. The box plots showed that the methylation �� value of particular promoter regions in the tissues. N indicated the number of sample size. **P

Published
2022
Full Text
View/download PDF

23. Reprogramming lipid metabolism prevents effector T cell senescence and enhances tumor immunotherapy

Author

Liu, Xia, primary, Hartman, Celine L., additional, Li, Lingyun, additional, Albert, Carolyn J., additional, Si, Fusheng, additional, Gao, Aiqin, additional, Huang, Lan, additional, Zhao, Yangjing, additional, Lin, Wenli, additional, Hsueh, Eddy C., additional, Shen, Lizong, additional, Shao, Qixiang, additional, Hoft, Daniel F., additional, Ford, David A., additional, and Peng, Guangyong, additional

Published
2021
Full Text
View/download PDF

24. Oxidized Lipoproteins Promote Resistance to Cancer Immunotherapy Independent of Patient Obesity

Author

Khojandi, Niloufar, primary, Kuehm, Lindsey M., additional, Piening, Alexander, additional, Donlin, Maureen J., additional, Hsueh, Eddy C., additional, Schwartz, Theresa L., additional, Farrell, Kaitlin, additional, Richart, John M., additional, Geerling, Elizabeth, additional, Pinto, Amelia K., additional, George, Sarah L., additional, Albert, Carolyn J., additional, Ford, David A., additional, Chen, Xiufen, additional, Kline, Justin, additional, and Teague, Ryan M., additional

Published
2021
Full Text
View/download PDF

29. Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial

Author

Crystal, Jessica S., Thompson, John F., Hyngstrom, John, Caracò, Corrado, Zager, Jonathan S., Jahkola, Tiina, Bowles, Tawnya L., Pennacchioli, Elisabetta, Beitsch, Peter D., Hoekstra, Harald J., Moncrieff, Marc, Ingvar, Christian, van Akkooi, Alexander, Sabel, Michael S., Levine, Edward A., Agnese, Doreen, Henderson, Michael, Dummer, Reinhard, Neves, Rogerio I., Rossi, Carlo Riccardo, Kane, John M., Trocha, Steven, Wright, Frances, Byrd, David R., Matter, Maurice, Hsueh, Eddy C., MacKenzie-Ross, Alastair, Kelley, Mark, Terheyden, Patrick, Huston, Tara L., Wayne, Jeffrey D., Neuman, Heather, Smithers, B. Mark, Ariyan, Charlotte E., Desai, Darius, Gershenwald, Jeffrey E., Schneebaum, Shlomo, Gesierich, Anja, Jacobs, Lisa K., Lewis, James M., McMasters, Kelly M., O’Donoghue, Cristina, van der Westhuizen, Andre, Sardi, Armando, Barth, Richard, Barone, Robert, McKinnon, J. Greg, Slingluff, Craig L., Farma, Jeffrey M., Schultz, Erwin, Scheri, Randall P., Vidal-Sicart, Sergi, Molina, Manuel, Testori, Alessandro A. E., Foshag, Leland J., Van Kreuningen, Lisa, Wang, He-Jing, Sim, Myung-Shin, Scolyer, Richard A., Elashoff, David E., Cochran, Alistair J., and Faries, Mark B.

Abstract

IMPORTANCE: Sentinel lymph node (SLN) biopsy is a standard staging procedure for cutaneous melanoma. Regional disease control is a clinically important therapeutic goal of surgical intervention, including nodal surgery. OBJECTIVE: To determine how frequently SLN biopsy without completion lymph node dissection (CLND) results in long-term regional nodal disease control in patients with SLN metastases. DESIGN, SETTING, AND PARTICIPANTS: The second Multicenter Selective Lymphadenectomy Trial (MSLT-II), a prospective multicenter randomized clinical trial, randomized participants with SLN metastases to either CLND or nodal observation. The current analysis examines observation patients with regard to regional nodal recurrence. Trial patients were aged 18 to 75 years with melanoma metastatic to SLN(s). Data were collected from December 2004 to April 2019, and data were analyzed from July 2020 to January 2022. INTERVENTIONS: Nodal observation with ultrasonography rather than CLND. MAIN OUTCOMES AND MEASURES: In-basin nodal recurrence. RESULTS: Of 823 included patients, 479 (58.2%) were male, and the mean (SD) age was 52.8 (13.8) years. Among 855 observed basins, at 10 years, 80.2% (actuarial; 95% CI, 77-83) of basins were free of nodal recurrence. By univariable analysis, freedom from regional nodal recurrence was associated with age younger than 50 years (hazard ratio [HR], 0.49; 95% CI, 0.34-0.70; P < .001), nonulcerated melanoma (HR, 0.36; 95% CI, 0.36-0.49; P < .001), thinner primary melanoma (less than 1.5 mm; HR, 0.46; 95% CI, 0.27-0.78; P = .004), axillary basin (HR, 0.61; 95% CI, 0.44-0.86; P = .005), fewer positive SLNs (1 vs 3 or more; HR, 0.32; 95% CI, 0.14-0.75; P = .008), and SLN tumor burden (measured by diameter less than 1 mm [HR, 0.39; 95% CI, 0.26-0.60; P = .001] or less than 5% area [HR, 0.36; 95% CI, 0.24-0.54; P < .001]). By multivariable analysis, younger age (HR, 0.57; 95% CI, 0.39-0.84; P = .004), thinner primary melanoma (HR, 0.40; 95% CI, 0.22-0.70; P = .002), axillary basin (HR, 0.55; 95% CI, 0.31-0.96; P = .03), SLN metastasis diameter less than 1 mm (HR, 0.52; 95% CI, 0.33-0.81; P = .007), and area less than 5% (HR, 0.58; 95% CI, 0.38-0.88; P = .01) were associated with basin control. When looking at the identified risk factors of age (50 years or older), ulceration, Breslow thickness greater than 3.5 mm, nonaxillary basin, and tumor burden of maximum diameter of 1 mm or greater and/or metastasis area of 5% or greater and excluding missing value cases, basin disease-free rates at 5 years were 96% (95% CI, 88-100) for patients with 0 risk factors, 89% (95% CI, 82-96) for 1 risk factor, 86% (95% CI, 80-93) for 2 risk factors, 80% (95% CI, 71-89) for 3 risk factors, 61% (95% CI, 48-74) for 4 risk factors, and 54% (95% CI, 36-72) for 5 or 6 risk factors. CONCLUSIONS AND RELEVANCE: This randomized clinical trial was the largest prospective evaluation of long-term regional basin control in patients with melanoma who had nodal observation after removal of a positive SLN. SLN biopsy without CLND cleared disease in the affected nodal basin in most patients, even those with multiple risk factors for in-basin recurrence. In addition to its well-validated value in staging, SLN biopsy may also be regarded as therapeutic in some patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00297895

Published
2022
Full Text
View/download PDF

43. Deprivation of arginine by recombinant human arginase in prostate cancer cells

Author

Hsueh Eddy C, Knebel Stephanie M, Lo Wai-Hung, Leung Yun-Chung, Cheng Paul, and Hsueh Chung-Tsen

Subjects
Arginase, Prostate cancer, Ornithine carbamoyl transferase, Argininosuccinate synthetase, Mammalian target of rapamycin, Autophagy, Diseases of the blood and blood-forming organs, RC633-647.5, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Recombinant human arginase (rhArg) has been developed for arginine deprivation therapy in cancer, and is currently under clinical investigation. During pre-clinical evaluation, rhArg has exhibited significant anti-proliferative activity in cancer cells deficient in the expression of ornithine carbamoyl transferase (OCT). Interestingly, a variety of cancer cells such as melanoma and prostate cancer deficient in argininosuccinate synthetase (ASS) are sensitive to arginine deprivation by arginine deiminase. In this study, we investigated levels of gene expression of OCT and ASS, and the effects of rhArg in human prostate cancer cells: LNCaP (androgen-dependent), PC-3 and DU-145 (both androgen-independent). Results Quantitative real-time PCR showed minimal to absent gene expression of OCT, but ample expression of ASS expression in all 3 cell lines. Cell viability assay after 72-h exposure of rhArg showed all 3 lines had half maximal inhibitory concentration less than or equal to 0.02 U/ml. Addition of ornithine to cell culture media failed to rescue these cells from rhArg-mediated cytotoxicity. Decreased phosphorylation of 4E-BP1, a downstream effector of mammalian target of rapamycin (mTOR), was noted in DU-145 and PC-3 after exposure to rhArg. Moreover, there was no significant apoptosis induction after arginine deprivation by rhArg in all 3 prostate cancer cell lines. Conclusion rhArg causes significant cytotoxicity in LNCaP, DU-145 and PC-3 prostate cancer cells which all demonstrate decreased OCT expression. Inhibition of mTOR manifested by hypophosphorylation of 4E-BP1 suggests autophagy is involved as alternative cell death mechanism. rhArg demonstrates a promising novel agent for prostate cancer treatment.

Published
2012
Full Text
View/download PDF

48. Guidance of sentinel lymph node biopsy decisions in patients with T1–T2 melanoma using gene expression profiling

Author

Vetto, John T, primary, Hsueh, Eddy C, additional, Gastman, Brian R, additional, Dillon, Larry D, additional, Monzon, Federico A, additional, Cook, Robert W, additional, Keller, Jennifer, additional, Huang, Xin, additional, Fleming, Andrew, additional, Hewgley, Preston, additional, Gerami, Pedram, additional, Leachman, Sancy, additional, Wayne, Jeffrey D, additional, Berger, Adam C, additional, and Fleming, Martin D, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results